BioNTech and Fosun Pharma Initiate P-ll Study of BNT162b2 Against COVID-19 in China

November 26, 2020 Auto Bot BioNTech, BNT162b2, China, Clinical Trial, Clinical Trials, Covid-19 Vaccine, Resumes 0

Shots:

  • The companies initiated the P-II study of their COVID-19 vaccine in China. The trial will generate data to support the BLA filing for approval of the vaccine in China
  • The study will be conducted by Jiangsu Provincial Center for Disease Control and Prevention. The study will commence with the recruitment of 960 patients aged b/w 18-85yrs.
  • In an ongoing P-III study, it met all 1EPs with an 95% efficacy rate in preventing symptomatic COVID-19 infection. The data supports the submission of an EUA to the US FDA on Nov 20, 2020

Click here ­to­ read full press release/ article | Ref: BioNTech | Image: World Pharma Day

The post BioNTech and Fosun Pharma Initiate P-ll Study of BNT162b2 Against COVID-19 in China first appeared on PharmaShots.